导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.12% | 1735/4773 |
| 近一周 | -2.67% | 2799/5462 |
| 近一月 | -4.24% | 2323/5421 |
| 近一季 | -3.75% | 1457/5209 |
| 近半年 | -4.74% | 2599/4920 |
| 近一年 | 7.10% | 1356/4366 |
| 近两年 | 69.64% | 979/2954 |
| 近三年 | 44.00% | 643/2253 |
| 成立以来 | 84.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.28% 1584/4961 |
8.35% 2604/5312 |
- - |
- - |
| 2025 | 30.54% 1308/4813 |
4.54% 916/3635 |
2.62% 1460/4076 |
20.12% 2030/4524 |
1.31% 1428/4813 |
| 2024 | 12.28% 1256/3463 |
0.67% 942/2808 |
-3.05% 1292/3014 |
14.55% 1955/3129 |
0.42% 1213/3463 |
| 2023 | -1.86% 538/2656 |
9.58% 402/2280 |
-2.38% 586/2385 |
-4.29% 1105/2515 |
-4.14% 889/2655 |
| 2022 | -9.06% 166/2207 |
-8.40% 280/1919 |
5.95% 806/2016 |
-8.87% 230/2113 |
2.83% 824/2208 |
| 2021 | 28.40% 82/1822 |
1.73% 244/1255 |
12.53% 327/1330 |
7.92% 170/1466 |
3.92% 382/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商中证500等权重指数增强A VS. 长安沪深300非周期A(740101) |